Showing results (1-10 of 109) with videos related to

Sort By:
Pageof 11
Bladder Cancer (Amsterdam, Netherlands)|July 5, 2016
Limited Funds for Bladder Cancer Research and What Can We Do About ItJoost L Boormans, Ellen C Zwarthoff
Acta Oncologica (Stockholm, Sweden)|July 26, 2022
Bladder-sparing (chemo)radiotherapy in elderly patients with muscle-invasive bladder cancer: a retrospective cohort studyNoortje Verschoor, Wilma D Heemsbergen, Joost L Boormans, et al.
Bladder Cancer (Amsterdam, Netherlands)|November 13, 2018
Hyperthermic Intravesical Chemotherapy for BCG Unresponsive Non-Muscle Invasive Bladder Cancer PatientsJoep J de Jong, Kees Hendricksen, Marloes Rosier, et al.
BJU International|February 12, 2005
Percutaneous nephrolithotomy for treating renal calculi in childrenJoost L Boormans, Jeroen R Scheepe, Carl F Verkoelen, et al.
Current Opinion in Urology|August 2, 2022
RNA-based urinary assays for non-muscle invasive bladder cancerOlga M Pijpers, Joep J de Jong, Tahlita C M Zuiverloon, et al.
Virchows Archiv : an International Journal of Pathology|April 28, 2021
PD-L1 expression in urothelial bladder cancer varies more among specimen types than between companion assaysJoep J de Jong, Hans Stoop, Joost L Boormans, et al.
BJU International|August 20, 2008
Histopathological characteristics of lymph node metastases predict cancer-specific survival in node-positive prostate cancerJoost L Boormans, Mark F Wildhagen, Chris H Bangma, et al.
European Urology|March 16, 2013
A 36-gene signature predicts clinical progression in a subgroup of ERG-positive prostate cancersDelila Gasi Tandefelt, Joost L Boormans, Hetty A van der Korput, et al.
Histopathology|July 14, 2018
Concordance of PD-L1 expression in matched urothelial bladder cancer specimensJoep J de Jong, Hans Stoop, Daan Nieboer, et al.
Pageof 11